Investors sentiment decreased to 1.31 in 2019 Q1. Its down 0.64, from 1.95 in 2018Q4. It turned negative, as 35 investors sold NeoGenomics, Inc. shares while 60 reduced holdings. 62 funds opened positions while 62 raised stakes. 75.90 million shares or 10.75% more from 68.54 million shares in 2018Q4 were reported.
Summit Creek Advisors Ltd Liability Corporation, a Minnesota-based fund reported 347,248 shares. Cwm Limited Liability Corporation has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO). Moreover, Rafferty Asset Mgmt Ltd Liability Co has 0.01% invested in NeoGenomics, Inc. (NASDAQ:NEO). Mutual Of America Management Limited Liability Company holds 0.03% or 94,168 shares. Alphaone Investment Serv Lc reported 0.98% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). 190,000 are owned by Strs Ohio. Mark Sheptoff Planning Limited Com holds 0.1% in NeoGenomics, Inc. (NASDAQ:NEO) or 6,900 shares. Franklin holds 0.02% or 1.49 million shares. Savings Bank Of America De, North Carolina-based fund reported 669,731 shares. Riverhead Cap Mngmt Ltd Liability Company owns 0.01% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 8,300 shares. Moreover, Principal Fincl Group Inc Inc has 0.02% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 813,871 shares. 11,679 were reported by Metropolitan Life Insurance Com. Trexquant Inv Limited Partnership holds 48,248 shares. Falcon Point Capital has invested 2.45% in NeoGenomics, Inc. (NASDAQ:NEO). Howland Capital Management Limited Liability Company has 0.05% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 31,337 shares.
Analysts expect NeoGenomics, Inc. (NASDAQ:NEO) to report $0.05 EPS on July, 23.They anticipate $0.02 EPS change or 66.67 % from last quarter’s $0.03 EPS. NEO’s profit would be $4.77M giving it 109.70 P/E if the $0.05 EPS is correct. After having $0.05 EPS previously, NeoGenomics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.86% or $0.4 during the last trading session, reaching $21.94. About 858,804 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has risen 109.52% since June 30, 2018 and is uptrending. It has outperformed by 105.09% the S&P500.
NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage
Among 3 analysts covering NeoGenomics (NASDAQ:NEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NeoGenomics had 5 analyst reports since January 3, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, February 20 by Needham. First Analysis maintained it with “Buy” rating and $23 target in Tuesday, March 12 report. The rating was maintained by Stephens with “Buy” on Wednesday, February 20.
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $2.10 billion. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It has a 348.25 P/E ratio. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.
More notable recent NeoGenomics, Inc. (NASDAQ:NEO) news were published by: Globenewswire.com which released: “NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder – GlobeNewswire” on December 12, 2018, also Fool.com with their article: “Here’s Why NeoGenomics Rocketed Higher Today – Motley Fool” published on January 09, 2019, Globenewswire.com published: “NeoGenomics Completes Acquisition of Genoptix, Inc. Nasdaq:NEO – GlobeNewswire” on December 10, 2018. More interesting news about NeoGenomics, Inc. (NASDAQ:NEO) were released by: Finance.Yahoo.com and their article: “3 Top Growth Stocks to Buy Right Now – Yahoo! Finance News” published on January 22, 2019 as well as Nasdaq.com‘s news article titled: “Ethereum’s ‘Killer’ NEO: The Best Altcoin to Watch? – Nasdaq” with publication date: July 17, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.